Back to top
more

Dr. Reddys Laboratories (RDY)

(Delayed Data from NYSE)

$81.22 USD

81.22
250,262

+0.38 (0.47%)

Updated Jul 26, 2024 04:00 PM ET

After-Market: $82.97 +1.75 (2.15%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 251)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for RDY

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Dr Reddy's Laboratories Ltd falls in the month of March.

All items in Millions except Per Share data.

3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Assets          
Cash & Equivalents 979 767 610 490 356
Receivables 963 882 880 679 667
Notes Receivable 0 0 0 0 0
Inventories 763 592 671 621 465
Other Current Assets 271 277 236 238 241
Total Current Assets 2,976 2,518 2,397 2,027 1,729
Net Property & Equipment 923 809 819 781 694
Investments & Advances 63 65 105 114 41
Other Non-Current Assets 0 0 1 2 23
Deferred Charges 129 88 108 145 162
Intangibles 494 427 417 549 420
Deposits & Other Assets 65 10 12 11 11
Total Assets 4,650 3,916 3,860 3,630 3,081
Liabilities & Shareholders Equity 3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Notes Payable 0 0 0 0 0
Accounts Payable 371 322 337 325 221
Current Portion Long-Term Debt 169 148 370 328 276
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 28 26 21 19 8
Other Current Liabilities 586 548 510 468 461
Total Current Liabilities 1,152 1,044 1,239 1,140 966
Mortgages 0 0 0 0 0
Deferred Taxes/Income 11 10 1 5 4
Convertible Debt 0 0 0 0 0
Long-Term Debt 72 16 76 86 17
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 49 36 33 33 38
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 1,284 1,106 1,348 1,264 1,025
Shareholders Equity 3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Preferred Stock 0 0 0 0 0
Common Stock (Par) 10 10 11 11 11
Capital Surplus 129 118 122 122 113
Retained Earnings 3,183 2,623 2,316 2,133 1,913
Other Equity 56 75 82 127 31
Treasury Stock 12 15 21 27 13
Total Shareholder's Equity 3,366 2,810 2,511 2,366 2,056
Total Liabilities & Shareholder's Equity 4,650 3,916 3,860 3,630 3,081
Total Common Equity 3,366 2,810 2,511 2,366 2,056
Shares Outstanding 166.80 166.50 166.40 166.20 165.70
Book Value Per Share 20.18 16.88 15.09 14.24 12.41

Fiscal Year End for Dr Reddy's Laboratories Ltd falls in the month of March.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents -99,999 979 877 827 756
Receivables NA 963 943 839 939
Notes Receivable NA 0 0 0 0
Inventories NA 763 731 681 639
Other Current Assets NA 271 318 274 228
Total Current Assets NA 2,976 2,867 2,620 2,562
Net Property & Equipment NA 923 875 848 819
Investments & Advances NA 63 100 71 60
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 129 131 130 116
Intangibles NA 494 496 497 516
Deposits & Other Assets NA 65 14 10 10
Total Assets NA 4,650 4,482 4,178 4,084
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 371 374 367 337
Current Portion Long-Term Debt NA 169 164 86 93
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 28 50 48 54
Other Current Liabilities NA 586 536 512 501
Total Current Liabilities NA 1,152 1,125 1,013 984
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 11 12 1 8
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 72 74 73 60
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 51 44 42
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 1,284 1,262 1,131 1,094
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 10 10 10 10
Capital Surplus NA 129 129 128 120
Retained Earnings NA 3,183 3,030 2,867 2,803
Other Equity NA 56 62 53 71
Treasury Stock NA 12 12 12 14
Total Shareholder's Equity NA 3,366 3,220 3,047 2,990
Total Liabilities & Shareholder's Equity NA 4,650 4,482 4,178 4,084
Total Common Equity 0 3,366 3,220 3,047 2,990
Shares Outstanding 166.80 166.80 166.80 166.80 166.60
Book Value Per Share 0.00 20.18 19.30 18.27 17.95